Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Xia,Jinbing; Li,Dengping; Zhu,Xiaoliang; Xia,Wenying; Qi,Zhenyong; Li,Guanhua; Xu,Qian

doi:10.3892/ol.2020.11457

Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Authors:
- Jinbing Xia
- Dengping Li
- Xiaoliang Zhu
- Wenying Xia
- Zhenyong Qi
- Guanhua Li
- Qian Xu
View Affiliations

Affiliations: Clinical Laboratory, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China, Department of CT Magnetic Resonance, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China, Department of Gastrointestinal Surgery, Yidu Central Hospital of Weifang, Qingzhou, Shandong 262500, P.R. China, Clinical Laboratory, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, Shandong 262700, P.R. China, Department of Respiratory Medicine, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China, Department of Medical Oncology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: March 11, 2020 https://doi.org/10.3892/ol.2020.11457
Pages: 3578-3586
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is one of the leading causes of global cancer-associated mortality. Aberrant microRNAs (miRs) have been reported to be involved in the pathogenesis of various cancer types. The present study aimed to investigate the expression profile and prognostic value of miR‑665 in patients with NSCLC, and to analyze its functional role in tumor progression using NSCLC cells. Reverse transcription‑quantitative PCR was used to estimate the expression levels of miR‑665. Kaplan‑Meier survival curves and Cox regression analysis were performed to evaluate the prognostic value of miR‑665. The effects of miR‑665 on NSCLC cell proliferation, migration and invasion were examined by cell transfection, and the target gene of miR‑665 was explored. miR‑665 expression was elevated in the tissue and cell samples of NSCLC. This increased miR‑665 expression was associated with lymph node metastasis and TNM stage. An independent association between miR‑665 and overall survival was identified in patients with NSCLC. When regulating the expression levels of miR‑665 in vitro, NSCLC cell proliferation, migration and invasion were enhanced by overexpression of miR‑665, but were inhibited by knockdown of miR‑665. The luciferase activity results indicated that the protein tyrosine phosphatase receptor type B (PTPRB) was a direct target of miR‑665 in NSCLC cells. The present study provided evidence for the clinical significance of a decreased expression of miR‑665 in the prognosis of NSCLC. Upregulation of miR‑665 contributed to tumor cell proliferation, migration and invasion by targeting PTPRB, suggesting the potential of miR‑665 as a candidate therapeutic target for NSCLC treatment.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
2	Akhurst T: Staging of non-small-cell lung cancer. PET Clin. 13:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
3	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7(pii): 1700702017. View Article : Google Scholar : PubMed/NCBI
4	Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
5	Wu DM, Liu T, Deng SH, Han R and Xu Y: SLC39A4 expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer. Sci Rep. 7:72112017. View Article : Google Scholar : PubMed/NCBI
6	Xue J, Yang J, Luo M, Cho WC and Liu X: MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opin Drug Discov. 12:141–157. 2017. View Article : Google Scholar : PubMed/NCBI
7	Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
8	Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
9	Hwang DW, Kim HY, Li F, Park JY, Kim D, Park JH, Han HS, Byun JW, Lee YS, Jeong JM, et al: In vivo visualization of endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy. Biomaterials. 121:144–154. 2017. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S, He L, Shan A, Zhang Y and Yu X: Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. Int J Nanomedicine. 13:1241–1256. 2018. View Article : Google Scholar : PubMed/NCBI
11	Liu J, Zhang X, Huang Y, Zhang Q, Zhou J, Zhang X and Wang X: miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol Lett. 17:1453–1460. 2019.PubMed/NCBI
12	An JC, Shi HB, Hao WB, Zhu K and Ma B: miR-944 inhibits lung adenocarcinoma tumorigenesis by targeting STAT1 interaction. Oncol Lett. 17:3790–3798. 2019.PubMed/NCBI
13	Dong M, Xie Y and Xu Y: miR-7-5p regulates the proliferation and migration of colorectal cancer cells by negatively regulating the expression of Krüppel-like factor 4. Oncol Lett. 17:3241–3246. 2019.PubMed/NCBI
14	Yang F, Chen L and Wang ZJ: MicroRNA-32 inhibits the proliferation, migration and invasion of human colon cancer cell lines by targeting E2F transcription factor 5. Eur Rev Med Pharmacol Sci. 23:4156–4163. 2019.PubMed/NCBI
15	Qiao G, Li J, Wang J, Wang Z and Bian W: miR-381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer. Int J Mol Med. 44:593–607. 2019.PubMed/NCBI
16	Li J, Yu M, Liu Z and Liu B: Clinical significance of serum miR-25 in non-small-cell lung cancer. Br J Biomed Sci. 76:111–116. 2019. View Article : Google Scholar : PubMed/NCBI
17	Jin X, Guan Y, Sheng H and Liu Y: Crosstalk in competing endogenous RNA network reveals the complex molecular mechanism underlying lung cancer. Oncotarget. 8:91270–91280. 2017. View Article : Google Scholar : PubMed/NCBI
18	Li C, Qin F, Hu F, Xu H, Sun G, Han G, Wang T and Guo M: Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles. Cell Biosci. 8:22018. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Zhu C, Huang Q and Zhu H: miR-383 inhibited the cell cycle progression of gastric cancer cells via targeting cyclin E2. DNA Cell Biol. 38:849–856. 2019. View Article : Google Scholar : PubMed/NCBI
21	Gao W, Zhang Y, Niu M, Bo Y, Li H, Xue X, Lu Y, Zheng X, Tang Y, Cui J, et al: Identification of miR-145-5p-centered competing endogenous RNA network in laryngeal squamous cell carcinoma. Proteomics. 19:e19000202019. View Article : Google Scholar : PubMed/NCBI
22	Tao L, Wu YQ and Zhang SP: MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma. 66:746–755. 2019. View Article : Google Scholar : PubMed/NCBI
23	Wang R, Li G, Zhuang G, Sun S and Song Z: Overexpression of microRNA-423-3p indicates poor prognosis and promotes cell proliferation, migration, and invasion of lung cancer. Diagn Pathol. 14:532019. View Article : Google Scholar : PubMed/NCBI
24	Chen S, Wang L, Yao B, Liu Q and Guoa C: miR-1307-3p promotes tumor growth and metastasis of hepatocellular carcinoma by repressing DAB2 interacting protein. Biomed Pharmacother. 117:1090552019. View Article : Google Scholar : PubMed/NCBI
25	Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B, Zhao J, Xia S, Fan S, Yu X, et al: Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 459:122–134. 2019. View Article : Google Scholar : PubMed/NCBI
26	Zou JG, Ma LF, Li X, Xu FL, Fei XZ, Liu Q, Bai QL and Dong YL: Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 23:1108–1115. 2019.PubMed/NCBI
27	Sun Y, Yang B, Lin M, Yu H, Chen H and Zhang Z: Identification of serum miR-30a-5p as a diagnostic and prognostic biomarker in colorectal cancer. Cancer Biomark. 24:299–305. 2019. View Article : Google Scholar : PubMed/NCBI
28	Du H, Xu Q, Xiao S, Wu Z, Gong J, Liu C, Ren G and Wu H: MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29. Life Sci. 224:1–11. 2019. View Article : Google Scholar : PubMed/NCBI
29	Wang SY, Li Y, Jiang YS and Li RZ: Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:4092–4097. 2017.PubMed/NCBI
30	Liang Z, Li X, Liu S, Li C, Wang X and Xing J: MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys Res Commun. 514:699–705. 2019. View Article : Google Scholar : PubMed/NCBI
31	Chen Z, Gao Y, Gao S, Song D and Feng Y: MiR-135b-5p promotes viability, proliferation, migration and invasion of gastric cancer cells by targeting Krüppel-like factor 4 (KLF4). Arch Med Sci. 16:167–176. 2019. View Article : Google Scholar : PubMed/NCBI
32	Long X, Shi Y, Ye P, Guo J, Zhou Q and Tang Y: MicroRNA-99a suppresses breast cancer progression by targeting FGFR3. Front Oncol. 9:14732020. View Article : Google Scholar : PubMed/NCBI
33	Hu Y, Yang C, Yang S, Cheng F, Rao J and Wang X: miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB. Cell Death Dis. 9:9542018. View Article : Google Scholar : PubMed/NCBI
34	Zhao XG, Hu JY, Tang J, Yi W, Zhang MY, Deng R, Mai SJ, Weng NQ, Wang RQ, Liu J, et al: miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 10:4792019. View Article : Google Scholar : PubMed/NCBI
35	Liu J, Jiang Y, Wan Y, Zhou S, Thapa S and Cheng W: MicroRNA-665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10. Mol Med Rep. 18:2661–2668. 2018.PubMed/NCBI
36	Qi Y, Dai Y and Gui S: Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC. Clin Exp Pharmacol Physiol. 43:1004–1012. 2016. View Article : Google Scholar : PubMed/NCBI